SCHEMBL2394924

SCHEMBL2394924

CCOC(=O)C(F)(F)c1ccccc1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PIN1 Q13526 1/20 0.45
LMNA P02545 2/20 0.44
FFAR4 Q5NUL3 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
RECQL P46063 1/20 0.40
MMP8 P22894 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13199349 0.85 PIN1 (0.50) POLBNPSR1PIN1LMNAMAPT
SCHEMBL2393385 0.84 TAAR1 (0.42) POLBNPSR1PIN1LMNASMN1; SMN2
SCHEMBL28846137 0.83 KCNN4 (0.44) POLBNPSR1FFAR4SMN1; SMN2ALDH1A1
SCHEMBL15314784 0.81 POLB (0.47) POLBNPSR1PIN1LMNAMAPT
SCHEMBL22426150 0.80 TSHR (0.47) POLBNPSR1PIN1LMNAMAPT
SCHEMBL1477878 0.80 POLB (0.46) POLBNPSR1PIN1LMNASMN1; SMN2
SCHEMBL31306500 0.80 CA12 (0.47) POLBNPSR1PIN1LMNASMN1; SMN2
SCHEMBL17420550 0.78 TDP1 (0.41) POLBNPSR1PIN1LMNAMAPT
SCHEMBL1171941 0.78 ACSS2 (0.48) POLBNPSR1PIN1MAPTALDH1A1
SCHEMBL31306448 0.78 ALDH1A1 (0.45) POLBNPSR1PIN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9102622-B2 Fatty acid amide hydrolase inhibitors UNIVERSITY OF CONNECTICUT (US) 2015-08-11 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 POLB 4657/4885NPSR1 2461/4885PIN1 3532/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 POLB 4657/4885NPSR1 2461/4885PIN1 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.